Booster Doses and Prioritizing Lives Saved

doi:10.1056/NEJMe2117592

Editorial

. 2021 Dec 23;385(26):2476-2477.

doi: 10.1056/NEJMe2117592. Epub 2021 Dec 8.

Booster Doses and Prioritizing Lives Saved

Minal K Patel¹

Affiliations

PMID: 34879192
PMCID: PMC8693686
DOI: 10.1056/NEJMe2117592

Editorial

Booster Doses and Prioritizing Lives Saved

Minal K Patel. N Engl J Med. 2021.

. 2021 Dec 23;385(26):2476-2477.

doi: 10.1056/NEJMe2117592. Epub 2021 Dec 8.

Author

Minal K Patel¹

Affiliation

¹ From the COVID-19 Response International Task Force, Centers for Disease Control and Prevention, Atlanta.

PMID: 34879192
PMCID: PMC8693686
DOI: 10.1056/NEJMe2117592

No abstract available

PubMed Disclaimer

Comment on

Protection against Covid-19 by BNT162b2 Booster across Age Groups.
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, Ash N, Huppert A, Milo R. Bar-On YM, et al. N Engl J Med. 2021 Dec 23;385(26):2421-2430. doi: 10.1056/NEJMoa2115926. Epub 2021 Dec 8. N Engl J Med. 2021. PMID: 34879188 Free PMC article.
BNT162b2 Vaccine Booster and Mortality Due to Covid-19.
Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, Yaron S. Arbel R, et al. N Engl J Med. 2021 Dec 23;385(26):2413-2420. doi: 10.1056/NEJMoa2115624. Epub 2021 Dec 8. N Engl J Med. 2021. PMID: 34879190 Free PMC article.

Cited by

Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.
Nakamura N, Kobashi Y, Kim KS, Park H, Tani Y, Shimazu Y, Zhao T, Nishikawa Y, Omata F, Kawashima M, Yoshida M, Abe T, Saito Y, Senoo Y, Nonaka S, Takita M, Yamamoto C, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, Jeong YD, Tatematsu D, Akao M, Sato Y, Iwanami S, Fujita Y, Wakui M, Aihara K, Kodama T, Shibuya K, Iwami S, Tsubokura M. Nakamura N, et al. PLOS Digit Health. 2024 May 3;3(5):e0000497. doi: 10.1371/journal.pdig.0000497. eCollection 2024 May. PLOS Digit Health. 2024. PMID: 38701055 Free PMC article.
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far.
Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. Chavda VP, et al. Vaccines (Basel). 2022 Nov 14;10(11):1926. doi: 10.3390/vaccines10111926. Vaccines (Basel). 2022. PMID: 36423021 Free PMC article. Review.
Multilevel determinants on COVID-19 booster intention among Americans.
Hao F. Hao F. Prev Med. 2022 Nov;164:107269. doi: 10.1016/j.ypmed.2022.107269. Epub 2022 Sep 23. Prev Med. 2022. PMID: 36162486 Free PMC article.
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
Adriaenssens N, Scholtes B, Bruyndonckx R, Van Ngoc P, Verbakel JYJ, De Sutter A, Heytens S, Van Den Bruel A, Desombere I, Van Damme P, Goossens H, Buret L, Duysburgh E, Coenen S. Adriaenssens N, et al. BMJ Open. 2022 Sep 19;12(9):e065897. doi: 10.1136/bmjopen-2022-065897. BMJ Open. 2022. PMID: 36123069 Free PMC article.
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
Cheng HL, Lim SM, Jia H, Chen MW, Ng SY, Gao X, Somani J, Sengupta S, Tay DMY, Chua PWL, R A, Ling SYH, McBee ME, Young BE, Sikes HD, Preiser PR. Cheng HL, et al. Microbiol Spectr. 2022 Oct 26;10(5):e0225722. doi: 10.1128/spectrum.02257-22. Epub 2022 Sep 7. Microbiol Spectr. 2022. PMID: 36069616 Free PMC article.

See all "Cited by" articles

References

1. World Health Organization. WHO Coronavirus (COVID-19) dashboard. 2021. (https://covid19.who.int/).
1. McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2021. November 03 (Epub ahead of print). - PMC - PubMed
1. International Vaccine Access Center, World Health Organization. Results of COVID-19 vaccine effectiveness studies: an ongoing systematic review — forest plots. 2021. (https://view-hub.org/sites/default/files/2021-10/COVID19%20VE%20Studies_...).
1. Feikin D, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. November 18, 2021. (https://ssrn.com/abstract=3961378). preprint. - PMC - PubMed
1. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2115624. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Supplementary concepts

Actions

Grants and funding

CC999999/ImCDC/Intramural CDC HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] World Health Organization. WHO Coronavirus (COVID-19) dashboard. 2021. (https://covid19.who.int/).

[2] World Health Organization. WHO Coronavirus (COVID-19) dashboard. 2021. (https://covid19.who.int/).

[3] McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2021. November 03 (Epub ahead of print). - PMC - PubMed

[4] McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2021. November 03 (Epub ahead of print). - PMC - PubMed

[5] International Vaccine Access Center, World Health Organization. Results of COVID-19 vaccine effectiveness studies: an ongoing systematic review — forest plots. 2021. (https://view-hub.org/sites/default/files/2021-10/COVID19%20VE%20Studies_...).

[6] International Vaccine Access Center, World Health Organization. Results of COVID-19 vaccine effectiveness studies: an ongoing systematic review — forest plots. 2021. (https://view-hub.org/sites/default/files/2021-10/COVID19%20VE%20Studies_...).

[7] Feikin D, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. November 18, 2021. (https://ssrn.com/abstract=3961378). preprint. - PMC - PubMed

[8] Feikin D, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. November 18, 2021. (https://ssrn.com/abstract=3961378). preprint. - PMC - PubMed

[9] Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2115624. - DOI - PMC - PubMed

[10] Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2115624. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Booster Doses and Prioritizing Lives Saved

Affiliation

Booster Doses and Prioritizing Lives Saved

Author

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical